Wafik El-Deiry: WIN Consortium in Cancer Personalized Medicine Is Supporting the Tempus AI GEMINI-NSCLC Study
Wafik El-Deiry, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University, shared a post on LinkedIn:
“Pleased to share that the WIN Consortium in cancer personalized medicine is supporting the activation of the Tempus AI GEMINI-NSCLC study at member institutions in the USA, Canada, Europe, and the Middle East.
The GEMINI-NSCLC study generates a robust, multi-omic dataset for research in biomarker discovery. The study includes two patient cohorts:
- Patients diagnosed with Stage IV NSCLC receiving standard-of-care first-line checkpoint inhibitor therapy
- Patients with early-stage NSCLC who are candidates for surgery and perioperative treatment
Tempus deploys its comprehensive molecular profiling platform – including solid tumor (xT/xR) and liquid biopsy (xF) – to analyze tumor biology longitudinally in the study. The study focuses on understanding disease progression and treatment response, with emphasis on identifying novel biomarkers and the use of circulating tumor DNA (ctDNA) to monitor MRD.”
Read more about the GEMINI-NSCLC study.
More posts featuring Wafik El-Deiry on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023